[Management of metastatic castration-resistant prostate cancer following docetaxel].

Abstract

Abiraterone acetate and cabazitaxel have shown an overall survival benefit in patients with metastatic castration-resistant prostate cancer following docetaxel failure. Both have been approved in this indication. The search, follow-up and characterisation of circulating tumor cells should help for the response evaluation and the choice between the two treatments. Recently, alpharadin (radium-223 chloride) has demonstrated also an overall survival advantage in a large phase III trial. Other hormone therapies as MDV3100 or TAK700 are very promising. In undifferentiated cancers with neuroendocrine features, etoposide and platinum salts combinations have shown low efficiency.

• Authors: Philippe Beuzeboc, Stanislas Ropert, François Goldwasser, Marc Zerbib
• Journal: Bulletin du cancer (Bull Cancer) Vol. 99 Suppl 1 Pg. S66-72 (Jul 2012) ISSN: 1769-6917 [Electronic] France
• Vernacular Title: Prise en charge des cancers de prostate résistants à la castration métastatiques après échec du docétaxel.
• PMID: 22516457 (Publication Type: Journal Article, Review)

Chemical References

• Androgen Antagonists
• Androstadienes
• Angiogenesis Inhibitors
• Antineoplastic Agents
• Benzamides
• Nitriles
• Radioisotopes
• Taxoids
• Docetaxel
• Phenylthiohydantoin
• cabazitaxel
• enzalutamide
• Abiraterone Acetate
• radium Ra 223 dichloride
• Radium

Topics

• Abiraterone Acetate
• Androgen Antagonists (therapeutic use)
• Androstadienes (therapeutic use)
• Angiogenesis Inhibitors (therapeutic use)
• Antineoplastic Agents (therapeutic use)
• Benzamides
• Docetaxel
• Humans
• Male
• Nitriles
• Orchiectomy
• Phenylthiohydantoin (analogs & derivatives, therapeutic use)
• Prognosis
• Prostatic Neoplasms (blood supply, drug therapy)
• Radioisotopes (therapeutic use)
• Radium (therapeutic use)
• Taxoids (therapeutic use)
• Treatment Failure